Select Publications
Conference Papers
2022, 'Pediatric Preclinical Testing Consortium Evaluation of the Anti-CD123 Antibody-Drug Conjugate, IMGN632, Against Patient-Derived Xenograft Models of Pediatric Acute Lymphoblastic Leukemia', in BLOOD, AMER SOC HEMATOLOGY, LA, New Orleans, pp. 8983 - 8984, presented at 64th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), LA, New Orleans, 10 December 2022 - 13 December 2022, http://dx.doi.org/10.1182/blood-2022-159867
,2022, 'Pediatric Preclinical Testing Consortium Evaluation of the MCL1 Inhibitor, AMG 176, Against Xenograft Models of Acute Lymphoblastic Leukemia', in BLOOD, AMER SOC HEMATOLOGY, LA, New Orleans, pp. 11690 - 11691, presented at 64th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), LA, New Orleans, 10 December 2022 - 13 December 2022, http://dx.doi.org/10.1182/blood-2022-159885
,2022, 'Establishment and application of patient-derived xenograft models for personalised medicine in paediatric cancer', Sydney, presented at Children’s Cancer Institute - Research Symposium 2022, Sydney, 06 December 2022
,2022, 'MULTI-PLATFORM TYROSINE KINASE PROFILING REVEALS NOVEL ACTIONABLE FGFR ABERRATIONS ACROSS PEDIATRIC AND ADOLESCENT AND YOUNG ADULT SARCOMAS', Vancouver, Canada, presented at Connective Tissue Oncology Society (CTOS) Annual Meeting 2022, Vancouver, Canada, 17 November 2022
,2021, 'Development of siRNA-loaded lipid nanoparticles targeting long non-coding RNA LINC01257 as a novel and safe therapeutic approach for paediatric acute myeloid leukaemia', in MOLECULAR CANCER THERAPEUTICS, AMER ASSOC CANCER RESEARCH, http://dx.doi.org/10.1158/1535-7163.TARG-21-P143
,2021, 'Multi-platform tyrosine kinase profiling reveals novel molecular response signatures to FGFR-inhibitors in paediatric and AYA sarcoma', Sydney (virtual), presented at Kids Cancer Alliance (KCA) Symposium 2021, Sydney (virtual), 02 September 2021
,2021, 'Abstract 3038: Evaluation of ROR1-targeted antibody-drug conjugates against ROR1-expressing pediatric preclinical models - a report from the pediatric preclinical testing consortium (PPTC)', in Cancer Research, American Association for Cancer Research (AACR), pp. 3038 - 3038, http://dx.doi.org/10.1158/1538-7445.am2021-3038
,2021, 'Abstract 3039: Pediatric preclinical testing consortium evaluation of the dual SYK/FLT3 inhibitor TAK-659 in xenograft models of pediatric acute lymphoblastic leukemia', in Cancer Research, American Association for Cancer Research (AACR), pp. 3039 - 3039, http://dx.doi.org/10.1158/1538-7445.am2021-3039
,2021, 'Abstract LB171: The differentiated CD47 monoclonal antibody AO-176 exhibits significant in vivo activity against xenograft models of pediatric acute lymphoblastic leukemia (ALL)', in Cancer Research, American Association for Cancer Research (AACR), pp. LB171 - LB171, http://dx.doi.org/10.1158/1538-7445.am2021-lb171
,2021, 'Supporting clinical decision-making for PI3K/AKT/mTOR inhibitors for high-risk paediatric and adolescent and young adult (AYA) sarcoma', Virtual, presented at The Australian and New Zealand Children’s Haematology/Oncology Group (ANZCHOG) Annual Scientific Meeting, Virtual, 24 June 2021
,2021, 'Multi-platform tyrosine kinase profiling reveals novel molecular response signatures to FGFR-inhibitors in paediatric and AYA sarcoma.', Virtual, presented at The Australian Society for Medical Research (ASMR) 2021, Virtual, 10 June 2021
,2020, 'Supporting clinical decision-making for PI3K/AKT/MTOR inhibitors for high-risk paediatric and AYA sarcoma', Virtual, presented at Connective Tissue Oncology Society (CTOS) Annual Meeting 2020, Virtual, 18 November 2020
,2020, 'Supporting clinical decision-making for PI3K/AKT/MTOR inhibitors for high-risk paediatric sarcoma patients', Virtual, presented at KCA Symposium 2020, Virtual, 17 September 2020
,2020, 'The XPO1 inhibitior, eltanexor, exhibits potent in vivo activity against a broad range of pediatric acute lymphoblastic leukemia subtypes', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, ELECTR NETWORK, presented at AACR Annual Meeting, ELECTR NETWORK, 22 June 2020 - 24 June 2020, http://dx.doi.org/10.1158/1538-7445.AM2020-4181
,2020, 'Precision medicine for high-risk paediatric and AYA sarcomas', Lorne, presented at Lorne Cancer 2020, Lorne, 13 February 2020
,2019, 'A Gain of Function Mutation in the NSD2 Histone Methyltransferase Drives Glucocorticoid Resistance Via Blocking Receptor Auto-Induction and BIM/Bmf Expression in ALL', in BLOOD, AMER SOC HEMATOLOGY, FL, Orlando, presented at 61st Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), FL, Orlando, 07 December 2019 - 10 December 2019, http://dx.doi.org/10.1182/blood-2019-126910
,2019, 'Pediatric Preclinical Testing Consortium Evaluation of the Novel Anti-Microtubule Drug E7130 in Xenograft Models of Early T-Cell Precursor Acute Lymphoblastic Leukemia', in BLOOD, AMER SOC HEMATOLOGY, FL, Orlando, presented at 61st Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), FL, Orlando, 07 December 2019 - 10 December 2019, http://dx.doi.org/10.1182/blood-2019-123867
,2019, 'Abstract A123: Reversal of glucocorticoid resistance in pediatric acute lymphoblastic leukemia is dependent on restoring BIM expression', in Molecular Cancer Therapeutics, American Association for Cancer Research (AACR), pp. a123 - a123, http://dx.doi.org/10.1158/1535-7163.targ-19-a123
,2019, 'The CXCR4 inhibitor X4-136 enhances the in vivo efficacy of established drugs against preclinical models of aggressive pediatric acute lymphoblastic leukemia', in MOLECULAR CANCER THERAPEUTICS, AMER ASSOC CANCER RESEARCH, http://dx.doi.org/10.1158/1535-7163.TARG-19-C004
,2019, 'Personalised medicine for high-risk paediatric and AYA sarcoma patients', Tokyo, Japan, presented at Connective Tissue Oncology Society (CTOS) Annual Meeting, Tokyo, Japan, 13 November 2019, https://www.ctos.org/Portals/0/PDF/2019%20CTOS%20Final%20Program.pdf
,2019, 'Precision medicine for high-risk paediatric and AYA sarcomas', Sydney, presented at Kids Cancer Alliance - Annual Meeting, Sydney, 31 October 2019, https://kca.org.au/wp-content/uploads/2019/11/2019-ECR-and-Student-Event-Program.pdf
,2019, 'Abstract 3839: Comparison of thio-deoxy-cytidine (TdCyd) and aza-thio-deoxy-cytidine (Aza-TdCyd) in solid and liquid tumor cell lines and PPTC pediatric xenografts', in Cancer Research, American Association for Cancer Research (AACR), pp. 3839 - 3839, http://dx.doi.org/10.1158/1538-7445.am2019-3839
,2019, 'Abstract LB-321: Re-evaluating sample sizes in preclinical testing of patient-derived xenografts', in Tumor Biology, American Association for Cancer Research, presented at Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA, http://dx.doi.org/10.1158/1538-7445.sabcs18-lb-321
,2019, 'Re-evaluating sample sizes in preclinical testing of patient-derived xenografts', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, GA, Atlanta, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), GA, Atlanta, 29 March 2019 - 03 April 2019, http://dx.doi.org/10.1158/1538-7445.AM2019-LB-321
,2018, 'A Single Mouse Trial Platform for Evaluation of Novel Agents in Acute Lymphoblastic Leukemia By the Pediatric Preclinical Testing Consortium', in BLOOD, AMER SOC HEMATOLOGY, CA, San Diego, presented at 60th Annual Meeting of the American-Society-of-Hematology (ASH), CA, San Diego, 01 December 2018 - 04 December 2018, http://dx.doi.org/10.1182/blood-2018-99-113207
,2018, 'Lymphocyte-specific chromatin accessibility predetermines glucocorticoid resistance in acute lymphoblastic leukemia', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, IL, Chicago, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), IL, Chicago, 14 April 2018 - 18 April 2018, http://dx.doi.org/10.1158/1538-7445.AM2018-3173
,2018, 'Pediatric Preclinical Testing Consortium evaluation of the menin inhibitor, VTP-50469, against xenograft models of MLL-rearranged infant acute lymphoblastic leukemia', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, IL, Chicago, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), IL, Chicago, 14 April 2018 - 18 April 2018, http://dx.doi.org/10.1158/1538-7445.AM2018-3187
,2018, 'Pediatric Preclinical Testing Consortium evaluation of 4 '-thio-2 '-deoxycytidine (TdCyd) and 5-aza-4 '-thio-2 '-deoxycytidine (Aza-TdCyd)', in MOLECULAR CANCER THERAPEUTICS, AMER ASSOC CANCER RESEARCH, http://dx.doi.org/10.1158/1535-7163.TARG-17-LB-B12
,2018, 'Pediatric Preclinical Testing Consortium evaluation of the second-generation selective inhibitor of nuclear export (SINE) compound KPT-8602', in MOLECULAR CANCER THERAPEUTICS, AMER ASSOC CANCER RESEARCH, http://dx.doi.org/10.1158/1535-7163.TARG-17-LB-B14
,2018, 'The AKR1C3-Activated Prodrug OBI-3424 Exerts Profound In Vivo Efficacy Against Preclinical Models of T-Cell Acute Lymphoblastic Leukemia (T-ALL); a Pediatric Preclinical Testing Consortium Study', in MOLECULAR CANCER THERAPEUTICS, AMER ASSOC CANCER RESEARCH, http://dx.doi.org/10.1158/1535-7163.TARG-17-LB-B16
,2017, 'The use of Murine Models of Chemosensitivity to Anticancer Agents in Childhood Cancer Clinical Care: Survivor, Parent and Community Acceptability and Willingness-to-Pay', in PEDIATRIC BLOOD & CANCER, WILEY, pp. S60 - S61, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000408978201113&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2017, 'Inhibition of NAMPT as a novel therapeutic strategy for infant leukemia', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, DC, Washington, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), DC, Washington, 01 April 2017 - 05 April 2017, http://dx.doi.org/10.1158/1538-7445.AM2017-1175
,2017, 'The nicotinamide phosphoribosyltransferase (NAMPT) inhibitor, OT-82, exhibits in vitro and in vivo efficacy against patient-derived xenograft models of high-risk acute lymphoblastic leukemia', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, DC, Washington, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), DC, Washington, 01 April 2017 - 05 April 2017, http://dx.doi.org/10.1158/1538-7445.AM2017-1942
,2015, 'Investigation of a Novel Cyclin-Dependent-Kinase (CDK) Inhibitor Cdki-73 As an Effective Treatment Option for MLL-AML', in BLOOD, AMER SOC HEMATOLOGY, FL, Orlando, presented at 57th Annual Meeting of the American-Society-of-Hematology, FL, Orlando, 05 December 2015 - 08 December 2015, http://dx.doi.org/10.1182/blood.V126.23.1365.1365
,2015, 'Abstract 1615: Initial testing (stage 1) of the Curaxin, CBL0137, by the Pediatric Preclinical Testing Program (PPTP)', in Cancer Research, American Association for Cancer Research (AACR), PA, Philadelphia, pp. 1615 - 1615, presented at 106th Annual Meeting of the American-Association-for-Cancer-Research (AACR), PA, Philadelphia, 18 April 2015 - 22 April 2015, http://dx.doi.org/10.1158/1538-7445.am2015-1615
,2015, 'Bioluminescence imaging enhances analysis of drug response in a patient-derived xenograft model of pediatric acute lymphoblastic leukemia', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, PA, Philadelphia, presented at 106th Annual Meeting of the American-Association-for-Cancer-Research (AACR), PA, Philadelphia, 18 April 2015 - 22 April 2015, http://dx.doi.org/10.1158/1538-7445.AM2015-1631
,2015, 'In vivo and in vitro efficacy of birinapant in preclinical models of Ph-like pediatric acute lymphoblastic leukemia', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, PA, Philadelphia, presented at 106th Annual Meeting of the American-Association-for-Cancer-Research (AACR), PA, Philadelphia, 18 April 2015 - 22 April 2015, http://dx.doi.org/10.1158/1538-7445.AM2015-1620
,2015, 'Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): a report from the Pediatric Preclinical Testing Program', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, PA, Philadelphia, presented at 106th Annual Meeting of the American-Association-for-Cancer-Research (AACR), PA, Philadelphia, 18 April 2015 - 22 April 2015, http://dx.doi.org/10.1158/1538-7445.AM2015-1616
,2014, '5-Aza-2 '-Deoxycytidine Promotes Cytotoxic Effect of CART-Cells on Leukaemia Cells', in BLOOD, AMER SOC HEMATOLOGY, CA, San Francisco, presented at 56th Annual Meeting of the American-Society-of-Hematology, CA, San Francisco, 06 December 2014 - 09 December 2014, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000349233806021&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2014, 'EARLY T-CELL PRECURSOR (ETP) ACUTE LYMPHOBLASTIC LEUKEMIA IS CHARACTERIZED BY ABERRANT ACTIVATION OF THE JAK/STAT PATHWAY AND PROFOUND RESPONSES TO RUXOLITINIB IN XENOGRAFT MODELS', in PEDIATRIC BLOOD & CANCER, WILEY-BLACKWELL, pp. S109 - S109, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000343932100014&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2014, 'Pediatric Preclinical Testing Program (PPTP) Evaluation of the p53-MDM2 Antagonist MK-8242', in EUROPEAN JOURNAL OF CANCER, ELSEVIER SCI LTD, SPAIN, European Org Res & Treatment Canc, Barcelona, pp. 131 - 131, presented at 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, SPAIN, European Org Res & Treatment Canc, Barcelona, 18 November 2014 - 21 November 2014, http://dx.doi.org/10.1016/S0959-8049(14)70536-2
,2014, 'The Pediatric Preclinical Testing Program (PPTP): Analysis of the first 10 years in vivo testing', in EUROPEAN JOURNAL OF CANCER, ELSEVIER SCI LTD, SPAIN, European Org Res & Treatment Canc, Barcelona, pp. 131 - 132, presented at 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, SPAIN, European Org Res & Treatment Canc, Barcelona, 18 November 2014 - 21 November 2014, http://dx.doi.org/10.1016/S0959-8049(14)70538-6
,2013, 'Effective Targeting Of The P53/MDM2 As In Preclinical Models Of Infant MLL-Rearranged Acute Lymphoblastic Leukemia', in BLOOD, AMER SOC HEMATOLOGY, LA, New Orleans, presented at 55th Annual Meeting of the American-Society-of-Hematology, LA, New Orleans, 07 December 2013 - 10 December 2013, http://dx.doi.org/10.1182/blood.V122.21.71.71
,2013, 'Cell and molecular determinants of in vivo efficacy of the BH3 mimetic ABT-263 against pediatric acute lymphoblastic leukemia xenografts', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, CA, San Diego, presented at AACR Special Conference on Pediatric Cancer at the Crossroads - Translating Discovery into Improved Outcomes, CA, San Diego, 03 November 2013 - 06 November 2013, http://dx.doi.org/10.1158/1538-7445.PEDCAN-B26
,2013, 'The selective targeting of cell survival pathways in leukemia', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, http://dx.doi.org/10.1158/1538-7445.FBCR13-A19
,2013, 'BET bromodomain inhibition as a therapeutic strategy to target N-Myc in neuroblastoma', in EUROPEAN JOURNAL OF CANCER, ELSEVIER SCI LTD, NETHERLANDS, Amsterdam, pp. S356 - S356, presented at European Cancer Congress 2013 - 17th ECCO / 38th ESMO / 32nd ESTRO, NETHERLANDS, Amsterdam, 27 September 2013 - 01 October 2013, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000326843602301&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2013, 'Abstract 2754: Pediatric Preclinical Testing Program (PPTP) stage 1 evaluation of the antimicrotubule agents cabazitaxel and docetaxel.', in Cancer Research, American Association for Cancer Research (AACR), pp. 2754 - 2754, http://dx.doi.org/10.1158/1538-7445.am2013-2754
,2013, 'Abstract 2758: Pediatric preclinical testing program (PPTP) stage 1 evaluation of MLN0128, a potent TOR kinase inhibitor.', in Cancer Research, American Association for Cancer Research (AACR), pp. 2758 - 2758, http://dx.doi.org/10.1158/1538-7445.am2013-2758
,2013, 'AKR1C3 is a potential biomarker of T-cell acute lymphoblastic leukemia sensitivity to the pre-prodrug PR-104.', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, Washington, DC, presented at 104th Annual Meeting of the American-Association-for-Cancer-Research (AACR), Washington, DC, 06 April 2013 - 10 April 2013, http://dx.doi.org/10.1158/1538-7445.AM2013-2745
,2013, 'High throughput screen to identify compounds that reverse glucocorticoid resistance in pediatric leukemia', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, DC, Washington, presented at 104th Annual Meeting of the American-Association-for-Cancer-Research (AACR), DC, Washington, 06 April 2013 - 10 April 2013, http://dx.doi.org/10.1158/1538-7445.AM2013-4550
,